Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Nephrology"
DOI: 10.1159/000523961
Abstract: Background: Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being developed to treat anemia in patients with chronic kidney disease (CKD) without dialysis dependency. Methods: In total, 588 patients with a clinical diagnosis of… read more here.
Keywords: desidustat; baseline; anemia due; dialysis ... See more keywords